[go: up one dir, main page]

WO2008126720A1 - 眼透明組織可視化用懸濁剤 - Google Patents

眼透明組織可視化用懸濁剤 Download PDF

Info

Publication number
WO2008126720A1
WO2008126720A1 PCT/JP2008/056449 JP2008056449W WO2008126720A1 WO 2008126720 A1 WO2008126720 A1 WO 2008126720A1 JP 2008056449 W JP2008056449 W JP 2008056449W WO 2008126720 A1 WO2008126720 A1 WO 2008126720A1
Authority
WO
WIPO (PCT)
Prior art keywords
eye
suspension
transparent tissue
visualization
microparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/056449
Other languages
English (en)
French (fr)
Inventor
Keiichi Matsuhisa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Priority to CN200880015343A priority Critical patent/CN101678042A/zh
Priority to EP08739562A priority patent/EP2140871A4/en
Priority to BRPI0811254-1A2A priority patent/BRPI0811254A2/pt
Priority to US12/594,671 priority patent/US20100076552A1/en
Priority to MX2009010596A priority patent/MX2009010596A/es
Priority to CA002682378A priority patent/CA2682378A1/en
Priority to JP2009509257A priority patent/JPWO2008126720A1/ja
Publication of WO2008126720A1 publication Critical patent/WO2008126720A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

　眼の透明組織の手術に際しその視認性を高めるための使用し易く且つ安全性に優れた手段として使用できる，眼透明組織可視化用懸濁剤が開示されている。この眼透明組織可視化用懸濁剤は，生分解性高分子化合物よりなる微粒子と、３価金属の塩及び２価金属の塩よりなる群より選ばれる少なくとも１種の塩とを水性媒質中に含有してなる。
PCT/JP2008/056449 2007-04-06 2008-04-01 眼透明組織可視化用懸濁剤 Ceased WO2008126720A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN200880015343A CN101678042A (zh) 2007-04-06 2008-04-01 眼部透明组织可视化用混悬剂
EP08739562A EP2140871A4 (en) 2007-04-06 2008-04-01 SUSPENSION FOR VISUALIZING TRANSPARENT OCULAR TISSUES
BRPI0811254-1A2A BRPI0811254A2 (pt) 2007-04-06 2008-04-01 Suspensão para visualização de tecido transparente em olho
US12/594,671 US20100076552A1 (en) 2007-04-06 2008-04-01 Suspension for visualization of transparent tissue in eye
MX2009010596A MX2009010596A (es) 2007-04-06 2008-04-01 Suspension para visualizacion de tejido transparente en el ojo.
CA002682378A CA2682378A1 (en) 2007-04-06 2008-04-01 Suspension for visualization of transparent tissue in eye
JP2009509257A JPWO2008126720A1 (ja) 2007-04-06 2008-04-01 眼透明組織可視化用懸濁剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007100060 2007-04-06
JP2007-100060 2007-04-06

Publications (1)

Publication Number Publication Date
WO2008126720A1 true WO2008126720A1 (ja) 2008-10-23

Family

ID=39863825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056449 Ceased WO2008126720A1 (ja) 2007-04-06 2008-04-01 眼透明組織可視化用懸濁剤

Country Status (10)

Country Link
US (1) US20100076552A1 (ja)
EP (1) EP2140871A4 (ja)
JP (1) JPWO2008126720A1 (ja)
KR (1) KR20100016167A (ja)
CN (1) CN101678042A (ja)
BR (1) BRPI0811254A2 (ja)
CA (1) CA2682378A1 (ja)
MX (1) MX2009010596A (ja)
RU (1) RU2455998C2 (ja)
WO (1) WO2008126720A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011016435A1 (ja) * 2009-08-04 2011-02-10 千寿製薬株式会社 ポリ乳酸粒子含有凍結乾燥組成物の製造方法
WO2011016436A1 (ja) * 2009-08-04 2011-02-10 千寿製薬株式会社 ポリ乳酸微粒子含有凍結乾燥組成物の製造方法
JP2016515618A (ja) * 2013-04-01 2016-05-30 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続的眼内放出のためのマイクロスフェア薬剤送達システム
JP2016528200A (ja) * 2013-07-11 2016-09-15 タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドＴａｓｌｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． 漢方薬微小滴丸剤の調製方法及びこの方法を用いて調製された漢方薬微小滴丸剤
US10626077B2 (en) 2013-08-29 2020-04-21 Tasly Pharmaceutical Group Co., Ltd. Salvianolic acid compound T, preparation method therefor, and use thereof
USRE49035E1 (en) 2013-07-11 2022-04-19 Tasly Pharmaceutical Group Co., Ltd. Traditional Chinese medicine composition, and preparation and application thereof
USRE49050E1 (en) 2013-07-11 2022-04-26 Tasly Pharmaceutical Group Co., Ltd. Traditional Chinese medicine composition, and preparation and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058159A1 (en) 1998-05-08 1999-11-18 Gerrit Reinold Jacob Melles The use of a vital dye for facilitating surgical procedures for vitreo-retinal surgery
WO2005115411A1 (ja) 2004-05-31 2005-12-08 Senju Pharmaceutical Co, .Ltd. 透明組織可視化剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW587943B (en) * 1998-01-13 2004-05-21 Kose Corp Powder composition, a powder dispersion in oil and a cosmetic composition containing said powder composition and a powder dispersion in oil
JP2001206850A (ja) * 2000-01-25 2001-07-31 Kuraray Co Ltd 眼組織再生誘導剤
AU2001291159A1 (en) * 2000-09-20 2002-04-02 Shahinian Jr., Lee Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7731941B2 (en) * 2004-12-06 2010-06-08 National University Corporation Kyushu University Staining composition for staining an ophthalmic membrane
EP3871693A1 (en) * 2005-09-27 2021-09-01 Special Water Patents B.V. Compositions for oral care

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058159A1 (en) 1998-05-08 1999-11-18 Gerrit Reinold Jacob Melles The use of a vital dye for facilitating surgical procedures for vitreo-retinal surgery
WO2005115411A1 (ja) 2004-05-31 2005-12-08 Senju Pharmaceutical Co, .Ltd. 透明組織可視化剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHALLA, J.K. ET AL., AUSTRALIAN AND NEW ZEALAND JOURNAL OF OPHTHALMOLOGY, vol. 26, 1998, pages 277
SAKAMOTO, T. ET AL., GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol. 240, 2002, pages 423
See also references of EP2140871A4 *
WINGATE, R.J. ET AL., NEW ZEALAND JOURNAL OF OPHTHALMOLOGY, vol. 27, 1999, pages 431

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011016435A1 (ja) * 2009-08-04 2011-02-10 千寿製薬株式会社 ポリ乳酸粒子含有凍結乾燥組成物の製造方法
WO2011016436A1 (ja) * 2009-08-04 2011-02-10 千寿製薬株式会社 ポリ乳酸微粒子含有凍結乾燥組成物の製造方法
JP2016515618A (ja) * 2013-04-01 2016-05-30 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続的眼内放出のためのマイクロスフェア薬剤送達システム
JP2016528200A (ja) * 2013-07-11 2016-09-15 タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドＴａｓｌｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． 漢方薬微小滴丸剤の調製方法及びこの方法を用いて調製された漢方薬微小滴丸剤
US11013694B2 (en) 2013-07-11 2021-05-25 Tasly Pharmaceutical Group Co., Ltd. Formulation of a micro drop pill and the preparation method thereof
USRE49035E1 (en) 2013-07-11 2022-04-19 Tasly Pharmaceutical Group Co., Ltd. Traditional Chinese medicine composition, and preparation and application thereof
USRE49050E1 (en) 2013-07-11 2022-04-26 Tasly Pharmaceutical Group Co., Ltd. Traditional Chinese medicine composition, and preparation and application thereof
US10626077B2 (en) 2013-08-29 2020-04-21 Tasly Pharmaceutical Group Co., Ltd. Salvianolic acid compound T, preparation method therefor, and use thereof

Also Published As

Publication number Publication date
EP2140871A4 (en) 2011-02-16
RU2455998C2 (ru) 2012-07-20
CN101678042A (zh) 2010-03-24
MX2009010596A (es) 2009-10-28
BRPI0811254A2 (pt) 2014-11-04
RU2009140969A (ru) 2011-05-20
JPWO2008126720A1 (ja) 2010-07-22
KR20100016167A (ko) 2010-02-12
CA2682378A1 (en) 2008-10-23
EP2140871A1 (en) 2010-01-06
US20100076552A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
WO2008126720A1 (ja) 眼透明組織可視化用懸濁剤
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
WO2008066700A3 (en) Methods and apparatus for natural orifice vaginal hysterectomy
EP2181722A3 (en) Delayed gelation compositions and methods of use
WO2008073985A3 (en) Laser energy device for soft tissue removal
EP2671584A3 (en) Compositions and methods for treating disorders associated with salt or fluid retention
WO2008060377A3 (en) Placental or umbilical cord tissue compositions
MX2009013255A (es) Matriz de solidificacion que incluye una sal de un acido mono-, di- o tri-carboxilico saturado de cadena recta.
WO2009086824A3 (de) Magnetische transducer
WO2009120919A3 (en) Fenofibrate dosage forms
MY150250A (en) Ketorolac tromethamine compositions for treating or preventing ocular pain
WO2012017166A3 (fr) Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
WO2011062420A3 (en) Nanoparticles for tumor-targeting and processes for the preparation thereof
GB0725024D0 (en) Instrument for removing tissue
BRPI0518928A2 (pt) suspensço oftÁlmica aquosa de rebamipide cristalino
DOP2011000329A (es) Preparacion de solido
MX386162B (es) Solución oftálmica que comprende diquafosol, método para producir la misma, y método para inhibir la formación de precipitado insoluble.
WO2012148850A3 (en) Radiopaque injectable nucleus hydrogel compositions
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
CL2008000444A1 (es) Quitosano, un derivado de quitosano soluble en agua y/o una sal del mismo para la aceleracion del ritmo de crecimiento de la una.
WO2013068707A8 (en) Compositions and methods relating to the stabilization of hydrophobically modified hydrophilic polymer treatment fluids under alkaline conditions
WO2006114439A3 (en) Novel nutraceutical compositions
RU2011134979A (ru) Композиция для снижения жесткости воды
WO2008011573A3 (en) Pre- and intra- operative imaging of testicular torsion

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880015343.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739562

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009509257

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2682378

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/010596

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12594671

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008739562

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20097022956

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3814/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009140969

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0811254

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091006